ACADIA Pharmaceuticals (FRA:DR6) Additional Paid-In Capital : €2,728.9 Mil(As of Mar. 2025)

View and export this data going back to 2004. Start your Free Trial

What is ACADIA Pharmaceuticals Additional Paid-In Capital?

ACADIA Pharmaceuticals's quarterly additional paid-in capital increased from Sep. 2024 (€2,634.9 Mil) to Dec. 2024 (€2,804.7 Mil) but then stayed the same from Dec. 2024 (€2,804.7 Mil) to Mar. 2025 (€2,728.9 Mil).

ACADIA Pharmaceuticals's annual additional paid-in capital increased from Dec. 2022 (€2,615.8 Mil) to Dec. 2023 (€2,625.0 Mil) and increased from Dec. 2023 (€2,625.0 Mil) to Dec. 2024 (€2,804.7 Mil).

ACADIA Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for ACADIA Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ACADIA Pharmaceuticals Additional Paid-In Capital Chart

ACADIA Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

2,147.61

2,384.76

2,615.75

2,624.96

2,804.71

ACADIA Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Additional Paid-In Capital	Get a 7-Day Free Trial															2,648.26	2,692.16	2,634.92	2,804.71	2,728.92

ACADIA Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

ACADIA Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of ACADIA Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

ACADIA Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ACADIA Pharmaceuticals Inc (FRA:DR6) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

ACAD:USA

Address

12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130

Website

https://www.acadia.com

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

ACADIA Pharmaceuticals Headlines

No Headlines